CFTR and cystic fibrosis: Another and highly salient test of the hypothesis would be provided by retrospective analysis of ataluren clinical trials for treatment of CF nonsense mutations, in which the nonsense mutation within each patient’s CFTR DNA was identified, including whether the mutation was dominant or recessive.